At the time of writing, shares in the regenerative medicine company are down 2.66% at a price of $6.23.
A look at the half-year results
For the half-year ending 31 December 2020, Avita Medical reported a substantial revenue increase from the sale of its goods. Revenue rose to $10.16 million up 56% from the previous corresponding period. However, despite the positive returns, net loss also expanded. The company posted a net loss of $15.87 million, which was up 13% from the first half of FY20.
The widening loss may be weighing on investors’ minds this afternoon as the stock is being sold off. But while shareholders will be regretting the fall, shorters of the stock will be pleased as the company continues its troubled run. Avita Medical remains the eighth most shorted stock on the ASX this week.
Critically it did not provide guidance to the market due to the prevailing uncertainty stemming from the coronavirus pandemic. The small-cap health share advised that its accounts were highly susceptible to the impacts of COVID-19 because its revenue came predominantly from 20 physicians.
About the Avita Medical share price
Avita Medical is a regenerative medicine company based in the United States. The company’s main offering is Recell, a spray-on treatment used for burn victims. Avita currently boasts a market capitalisation of $136 million.
The Avita share price has had a torrid time of late and is down 63% on the same time last year. The share has not fully recovered from the impacts of COVID-19 and remains some way off its 52-week high of $9.11.